CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide

BACKGROUND: Rhabdomyosarcoma (RMS) is a small round blue cell malignant tumor, representing 7% of childhood malignancies, and over 50% of all soft tissue sarcomas. Cyclophosphamide (CPA) is a prodrug and is the mainstay of RMS treatment. CYP2B6 is a highly polymorphic drug metabolizing enzyme involv...

Descripción completa

Detalles Bibliográficos
Autores principales: Labib, Rania M., A. Abdelrahim, Mohamed E., Elnadi, Enas, Hesham, Reem M., Yassin, Dina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936837/
https://www.ncbi.nlm.nih.gov/pubmed/27388155
http://dx.doi.org/10.1371/journal.pone.0158890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936837/
https://www.ncbi.nlm.nih.gov/pubmed/27388155
http://dx.doi.org/10.1371/journal.pone.0158890

Ejemplares similares